Clinical re evaluation and application transformation of traditional Chinese medicine in the treatment of difficult skin diseases

Efficacy and safety evaluation of Jianpi Jiedu pill in the treatment of psoriasis vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005536

Enrollment

Unknown

Registered

2022-01-14

Start date

2022-01-25

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

control group:Jianpi Jiedu pill simulant

Test group:Jianpi Jiedu pill oral

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Patients with spleen deficiency and dampness excess syndrome of psoriasis vulgaris were definitely diagnosed; ? Age 18 ~ 70 years old; ? The course of disease was 0 ~ 20 years; ? Informed consent, voluntary treatment, observation and examination.

Exclusion criteria

Exclusion criteria: ? Arthritis type, pustular type, erythroderma type psoriasis; ? Systematic treatment within 3 months, including large-area topical use of powerful cortical sterols or immunosuppressants; ? Patients with serious primary diseases or psychosis such as cardio cerebrovascular, liver and kidney and hematopoietic system; ? Pregnant, pregnant or lactating women; ? Those who fail to use drugs according to regulations, cannot judge the curative effect, or incomplete data affect the judgment of curative effect or safety.

Design outcomes

Primary

Measure	Time frame
PASI;Recurrence rate of psoriasis;	—

Secondary

Measure	Time frame
VAS;Dosage of Western medicine for external use;SDS;Onset time;rebound rate;time to relapse;DLQI;SAS;BSA;	—

Countries

China

Contacts

Public ContactLiu Hongxia

1877538293@qq.com13999872599

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026